Cargando…
Genomic Profiling of T-Cell Neoplasms Reveals Frequent JAK1 and JAK3 Mutations With Clonal Evasion From Targeted Therapies
PURPOSE: The promise of precision oncology is that identification of genomic alterations will direct the rational use of molecularly targeted therapy. This approach is particularly applicable to neoplasms that are resistant to standard cytotoxic chemotherapy, like T-cell leukemias and lymphomas. In...
Autores principales: | Greenplate, Allison, Wang, Kai, Tripathi, Rati M., Palma, Norma, Ali, Siraj M., Stephens, Phil J., Miller, Vincent A., Shyr, Yu, Guo, Yan, Reddy, Nishitha M., Kozhaya, Lina, Unutmaz, Derya, Chen, Xueyan, Irish, Jonathan M., Davé, Utpal P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6072266/ https://www.ncbi.nlm.nih.gov/pubmed/30079384 http://dx.doi.org/10.1200/PO.17.00019 |
Ejemplares similares
-
Expression and Function of TNF and IL-1 Receptors on Human Regulatory T Cells
por: Mercer, Frances, et al.
Publicado: (2010) -
Germline-somatic JAK2 interactions are associated with clonal expansion in myelofibrosis
por: Brown, Derek W., et al.
Publicado: (2022) -
Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion
por: Albacker, Lee A., et al.
Publicado: (2017) -
The JAK2V617F-bearing vascular niche promotes clonal expansion in myeloproliferative neoplasms
por: Zhan, H, et al.
Publicado: (2018) -
Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies
por: Passamonti, Francesco, et al.
Publicado: (2011)